Price
Financials
Standalone, Rs crore| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 69 | 62 | 68 | 66 | 78 | 93 |
| Expenses | 58 | 56 | 61 | 59 | 72 | 87 |
| Operating Profit | 11 | 6 | 7 | 7 | 6 | 6 |
| OPM % | 16% | 9% | 10% | 10% | 8% | 6% |
| Other Income | -1 | 2 | 1 | 1 | 2 | 3 |
| Interest | 1 | 2 | 1 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 2 | 3 | 3 |
| Profit before tax | 8 | 6 | 6 | 4 | 2 | 3 |
| Tax % | 25% | 32% | 0% | 59% | 0% | 48% |
| Net Profit | 6 | 4 | 6 | 1 | 2 | 2 |
| EPS in Rs | 4.75 | 2.24 | 3.34 | 0.84 | 1.36 | 0.94 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 78 | 72 | 92 | 115 | 131 | 132 | 171 |
| Expenses | 71 | 64 | 85 | 105 | 114 | 119 | 158 |
| Operating Profit | 7 | 7 | 7 | 9 | 17 | 14 | 12 |
| OPM % | 9% | 10% | 8% | 8% | 13% | 10% | 7% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 2 | 5 |
| Interest | 1 | 1 | 2 | 2 | 3 | 4 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 3 | 6 |
| Profit before tax | 5 | 5 | 4 | 7 | 13 | 9 | 5 |
| Tax % | 30% | 33% | 27% | 27% | 28% | 23% | 27% |
| Net Profit | 3 | 3 | 3 | 5 | 10 | 7 | 4 |
| EPS in Rs | 5.56 | 4.18 | 2.30 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 19% | 14% | 29% | ||
| Compounded Profit Growth | % | 6% | -6% | -44% | ||
| Stock Price CAGR | % | % | % | -31% | ||
| Return on Equity | % | 15% | 12% | 6% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 0.40 | 0.40 | 17 | 17 | 17 |
| Reserves | 6 | 9 | 12 | 17 | 45 | 52 | 56 |
| Borrowings | 12 | 15 | 17 | 25 | 24 | 49 | 55 |
| Other Liabilities | 25 | 21 | 37 | 54 | 48 | 44 | 59 |
| Total Liabilities | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
| Fixed Assets | 6 | 9 | 10 | 11 | 11 | 40 | 37 |
| CWIP | 3 | 0 | 0 | 0 | 4 | 3 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 35 | 37 | 56 | 86 | 119 | 118 | 136 |
| Total Assets | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 3 | -1 | 5 | -4 | -16 | -5 | 9 |
| Cash from Investing Activity | -5 | -2 | -3 | -2 | -5 | -31 | -14 |
| Cash from Financing Activity | 1 | 3 | -1 | 6 | 30 | 28 | 5 |
| Net Cash Flow | -0 | -0 | 1 | -0 | 9 | -8 | 0 |
| Free Cash Flow | -1 | -2 | 2 | -6 | -21 | -37 | -5 |
| CFO/OP | 71% | 7% | 88% | -27% | -70% | -25% | 86% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 119 | 128 | 157 | 188 | 167 | 157 |
| Inventory Days | 29 | 52 | 61 | 249 | 277 | 257 | |
| Days Payable | 155 | 155 | 173 | 412 | 281 | 337 | |
| Cash Conversion Cycle | -7 | 17 | 16 | 157 | 25 | 163 | 77 |
| Working Capital Days | 14 | 24 | 21 | 39 | 111 | 91 | 74 |
| ROCE % | 28% | 24% | 25% | 28% | 13% | 9% |
| Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Promoters | 69.98% | 69.98% | 69.98% | 69.98% | 69.98% |
| FIIs | 5.81% | 0.42% | 0.06% | 0.00% | 0.00% |
| DIIs | 1.93% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 22.28% | 29.60% | 29.96% | 30.02% | 30.02% |
| No. of Shareholders | 1,117 | 1,355 | 1,544 | 1,466 | 1,435 |
Fundamentals
Market Cap₹ 77.8 Cr.
Current Price₹ 45.4
Stock P/E18.9
Book Value₹ 42.8
ROCE9.08 %
ROE5.76 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)29%
Compounded Profit Growth (TTM)-44%
Standalone figures.
Valuation
Market capRs 72 Cr
Enterprise valueRs 97 Cr
P/E (TTM)14.78x
Price to book4.07x
Price to sales0.63x
EV / EBITDA9.46x
EV / EBIT10.83x
EV / sales0.85x
Earnings yield6.77%
Profitability
Operating margin (excl. other income)7.90%
Operating margin (incl. other income)8.99%
EBITDA margin8.99%
Pre-tax margin5.82%
Net profit margin4.26%
ROE31.92%
ROCE24.70%
ROA5.97%
ROE, 3-year average32.78%
ROCE, 3-year average25.56%
ROA, 3-year average6.16%
ROIC (approx.)15.34%
Tax rate26.73%
Other income / net worth6.99%
Growth
Sales growth (latest year)24.98%
Profit growth (latest year)52.02%
Sales CAGR, 3 years13.56%
Profit CAGR, 3 years12.80%
Per share
EPS (TTM)Rs 2.85
EPS (latest year)Rs 122.00
EPS, 3-year averageRs 93.00
Book value per shareRs 10.34
Sales per shareRs 66.78
Cash flow per shareRs -2.49
Free cash flow per shareRs -2.92
Efficiency
Asset turnover1.18x
Fixed asset turnover10.58x
Inventory turnover3.60x
Inventory days101 days
Debtor days157 days
Debtors turnover2.32x
Creditor days337 days
Cash conversion cycle77 days
Working capital days74 days
Leverage
Total debtRs 25 Cr
Cash and bankRs 0 Cr
Net debtRs 25 Cr
Debt to equity1.43x
Net debt / EBITDA2.45x
Interest coverage3.86x
Owners' fund to total sources18.24%
Debt to assets26.15%
Cash flow
Cash from Operating Activity (latest year)Rs -4 Cr
Cash from Investing Activity (latest year)Rs -2 Cr
Cash from Financing Activity (latest year)Rs 6 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -5 Cr
FCFE (approx.: FCF + change in debt)Rs 4 Cr
Cash from ops / profit, 5 years-0.38x
Statement figures
Net sales (TTM)Rs 115 Cr
Net sales (latest year)Rs 115 Cr
Operating profit excl. other income (latest year)Rs 9 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs 10 Cr
PBDT (TTM)Rs 8 Cr
Profit before tax (TTM)Rs 7 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 5 Cr
Net profit (latest year)Rs 5 Cr
Depreciation (TTM)Rs 1 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 85 Cr
Total expenditure (latest year)Rs 105 Cr
Total income (latest year)Rs 116 Cr
Share capitalRs 0 Cr
ReservesRs 17 Cr
Shareholders' fundsRs 18 Cr
Total assetsRs 97 Cr
Net blockRs 11 Cr
InvestmentsRs 0 Cr
ReceivablesRs 49 Cr
InventoryRs 24 Cr
Other liabilitiesRs 54 Cr
Shares outstanding (crore)1.71
Ownership
Promoter holding69.98% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 14.8 is the lowest in its own 2.8-year history
(median 35.2, low 14.8, high 76.4).
P/B 4.07 is the lowest in 2.8 years (median 9.53).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | ZENITHDRUG | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -14.1% | -2.8% | -11.3 pts |
| 1 month | -0.1% | -6.8% | +6.7 pts |
| 3 months | -8.8% | -7.6% | -1.2 pts |
| 6 months | +2.6% | +0.4% | +2.2 pts |
| 1 year | -34.8% | -9.9% | -24.8 pts |
| 2 years | -63.5% | -13.6% | -49.9 pts |
Red flags
F-score 4 of 8| explain | Weak cash conversion Cash from operations was -2% of net profit over the last 3 years |
| explain | Receivables outrunning sales Receivables grew 54% vs sales +25% in 2026 |
| look | Inventory outrunning sales Inventory grew 95% vs sales +25% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹93 Cr +50.0% vs Mar 2024.
Net profit ₹2 Cr -50.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 daysSME scrip is not regularly traded
Quick answers
What is the market cap of Zenith Drugs Ltd?
Zenith Drugs Ltd (ZENITHDRUG) has a market capitalisation of Rs 77.8 Cr. at the 2026-10-01 close.
What is the P/E ratio of Zenith Drugs Ltd?
Zenith Drugs Ltd trades at a P/E of 18.9 on trailing twelve-month profit, at the 2026-10-01 close.
What were Zenith Drugs Ltd's latest quarterly results?
In the Mar 2026 quarter, Zenith Drugs Ltd sales was Rs 93 Cr (+50.0% vs Mar 2024) and net profit was Rs 2 Cr.
What is the 52-week high and low of Zenith Drugs Ltd?
The 52-week high is Rs 73.45 and the 52-week low is Rs 33.30.